Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Rating of Moderate Buy from Analysts

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK – Free Report) have earned an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating on the company. The average twelve-month price objective among […]

Related Keywords

United States ,America ,Fady Ibraham Malik ,Roberti Blum ,Chilton Capital Management ,Jpmorgan Chase Co ,Prelude Capital Management ,Saturnv Capital Management ,Cantor Fitzgerald ,Securities Exchange Commission ,Cytokinetics Company Profile ,Cytokinetics Incorporated ,Free Report ,Exchange Commission ,Ibraham Malik ,Capital Management ,Cytokinetics Daily ,Cytokinetics ,Nasdaq Cytk ,Cytk ,Medical ,Ratings ,Consensus ,